ArticleAmerican journal of cancer research2024

Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet.

Yao-Yu Hsieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.